The motor symptoms of Parkinson's disease (PD) are due to the progressive loss of
dopamine (DA) neurons in substantia nigra pars compacta (SNc). Nothing is known to slow …

Ca2+-influx through L-type Ca2+-channels (LTCCs) is associated with activity-related
stressful oscillations of Ca2+ levels within dopaminergic (DA) neurons in the substantia …

The motor symptoms of Parkinson's disease (PD) mainly arise from degeneration of
dopamine neurons within the substantia nigra. As no disease-modifying PD therapies are …

Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of
novel treatments for motor symptoms of PD and in the search for clues to the underlying …

Parkinson's disease (PD) is the second most common neurodegenerative disease in the
world. Its causes are poorly understood and there is no proven therapeutic strategy for …

Animal models of Parkinson's disease (PD) have been widely used in the past four decades
to investigate the pathogenesis and pathophysiology of this neurodegenerative disorder …

Functional models of Parkinson's disease (PD) have led to effective treatment for the motor
symptoms. Toxin‐based models, such as the 6‐hydroxydopamine–lesioned rat and 1 …

The novel naphtoxazine derivative and preferential D3 vs D2 receptor agonist, S32504,
restores perturbed motor function in rodent and primate models of antiparkinsonian activity …

Formidable challenges for Parkinson's disease (PD) research are to understand the
processes underlying nigrostriatal degeneration and how to protect dopamine neurons …

During the last 20 years, an enormous research effort and hundreds of millions of dollars
have been spent attempting to develop and prove that drugs may slow the rate of …